Current Report Filing (8-k)
March 02 2020 - 7:43AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): March 2, 2020
ENDONOVO
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-55453
|
|
45-2552528
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
6320
Canoga Avenue, 15th Floor
Woodland
Hills, CA 91367
(Address
of principal executive office)(Zip Code)
Registrant’s
telephone number, including area code: (800) 489-4774
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
Common
Stock, par value $0.0001 per share
|
|
ENDV
|
|
OTCQB
|
Item
8.01 Other Events.
On
March 2, 2020, the Registrant’s released a presentation on SofPulse® the company’s flagship Electrocuetical®
device. The presentation will be utilized to expand the current US market rollout for SofPulse® and will be presented at various
upcoming investment and medical conferences, seminars, presentations and institutional investor meetings.
Item
9.01 Financial Statements and Exhibits.
(a) Financial
Statements
None
(b) Exhibits
99.1 Presentation regarding SofPulse®.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
March 2, 2020
|
|
ENDONOVO
THERAPEUTICS, INC.
|
|
|
|
|
|
|
By:
|
/s/
Alan Collier
|
|
|
|
Alan
Collier
|
|
|
|
Chief
Executive Officer
|
Endonovo Therapeutics (PK) (USOTC:ENDV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endonovo Therapeutics (PK) (USOTC:ENDV)
Historical Stock Chart
From Sep 2023 to Sep 2024
